Medical Affairs and Evidence Generation Asset Lead –Executive Director (Lima)

Medical Affairs and Evidence Generation Asset Lead –Executive Director (Lima)

04 oct
|
argenx
|
Lima

04 oct

argenx

Lima

Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.
We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients.
Medical Affairs and Evidence Generation Asset Lead -Executive Director
The Medical Affairs and Evidence Generation (MA⪚) Asset Lead provides expert medical insights to inform indication selection, target product profile development, clinical development plans,



and pre-launch and commercialization strategies working with general cross-functional team members from science, clinical development, medical affairs and evidence generation, and commercial. This strategic leader serves in a "player coach" capacity with responsibilities for the Integrated Evidence Generation Plans and other relevant MA⪚ activities working with the broader MA⪚ community members who support the asset. Additionally, as the molecule moves through its lifecycle this individual will also serve as a people manager with responsibilities for hiring, coaching, and developing MA⪚ indication leads for the asset.
Specifically, this position is the MA⪚ Strategy Lead for ARGX-121, a novel anti-IgA monoclonal antibody engineered to selectively remove pathogenic IgA from circulation and inhibit IgA-mediated inflammatory signaling. By combining FcRn-mediated IgA sweeping with blockade of the IgA receptor FcαRI (CD89), ARGX-121 is designed to address the root cause of IgA-driven

📌 Medical Affairs and Evidence Generation Asset Lead –Executive Director (Lima)
🏢 argenx
📍 Lima

Postulate a este anuncio

Muestra tus habilidades a la empresa, rellenar el formulario y deja un toque personal en la carta, ayudará el reclutador en la elección del candidato.

Suscribete a esta alerta:

Recibe por email las nuevas ofertas de trabajo para: medical affairs and evidence generation asset lead –executive director (lima) / lima

Suscribete a esta alerta:

Recibe por email las nuevas ofertas de trabajo para: medical affairs and evidence generation asset lead –executive director (lima) / lima